R
Roger S. Blumenthal
Researcher at Johns Hopkins University
Publications - 828
Citations - 50648
Roger S. Blumenthal is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 94, co-authored 746 publications receiving 40461 citations. Previous affiliations of Roger S. Blumenthal include Johns Hopkins University School of Medicine & Houston Methodist Hospital.
Papers
More filters
Journal ArticleDOI
Global Prevalence and Impact of Hostility, Discrimination, and Harassment in the Cardiology Workplace
Garima Sharma,Pamela S. Douglas,Sharonne N. Hayes,Roxana Mehran,MA Anne K. Rzeszut,Robert A. Harrington,Athena Poppas,Mary Norine Walsh,Toniya Singh,Ranna Parekh,Roger S. Blumenthal,Laxmi S. Mehta +11 more
TL;DR: In this paper, the authors evaluated emotional harassment, discrimination, and sexual harassment experienced by cardiologists and its impact on professional satisfaction and patient interactions worldwide, and found that gender was the most frequent cause of discrimination (44%), followed by age (37%), race (24), religion (15%), and sexual orientation (5%).
Journal ArticleDOI
Implications of coronary artery calcium testing on risk stratification for lipid-lowering therapy according to the 2016 European Society of Cardiology recommendations: The MESA study:
Márcio Sommer Bittencourt,Ron Blankstein,Michael J. Blaha,Veit Sandfort,Arthur S. Agatston,Matthew J. Budoff,Roger S. Blumenthal,Harlan M. Krumholz,Khurram Nasir +8 more
TL;DR: The absence of coronary artery calcium is associated with a low incidence of cardiovascular mortality or coronary heart disease events even in individuals in whom lipid-lowering therapy is recommended.
Journal ArticleDOI
The Case For and Against a Coronary Artery Calcium Trial: Means, Motive, and Opportunity.
John W. McEvoy,Seth S. Martin,Michael J. Blaha,Tamar S. Polonsky,Khurram Nasir,Sanjay Kaul,Philip Greenland,Roger S. Blumenthal +7 more
TL;DR: The arguments for and against expanded CAC testing based on clinical, safety and economic considerations are reviewed and potential trial approaches based on recent changes in clinical practice that could make a new CAC trial design feasible are proposed.
Journal ArticleDOI
Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Associations of Low Circulating Low‐Density Lipoprotein Concentration With Subclinical Coronary Atherosclerosis
Jon T. Giles,Mary Chester M. Wasko,Cecilia P. Chung,Moyses Szklo,Roger S. Blumenthal,Amy H. Kao,Sabahat Bokhari,Afshin Zartoshti,C. Michael Stein,Joan M. Bathon +9 more
TL;DR: Rheumatoid arthritis patients with the lowest circulating low‐density lipoprotein (LDL) concentrations are at heightened risk of cardiovascular events, but the atherosclerosis burden within this subgroup is unknown.
Journal ArticleDOI
Relation of physical activity to prevalence of nonalcoholic Fatty liver disease independent of cardiometabolic risk.
Ebenezer T Oni,Ebenezer T Oni,Rohan Kalathiya,Ehimen Aneni,Seth S. Martin,Michael J. Blaha,Theodore Feldman,Arthur S. Agatston,Roger S. Blumenthal,Raquel D. Conceição,Jose A.M. Carvalho,Raul D. Santos,Khurram Nasir +12 more
TL;DR: PA presents a dose-response association with NAFLD independent of the MS or obesity, and the results are compatible with the idea that benefits of PA are relevant to everyone regardless of cardiometabolic risk.